title: CENTRAL SEROUS CHORIORETINOPATHY TREATED WITH MINERALOCORTICOID ANTAGONISTS: A ONE-YEAR PILOT STUDY.
abstract: OBJECTIVE
  To assess the treatment response to mineralocorticoid antagonists in a pilot study of patients diagnosed with central serous chorioretinopathy using multimodal imaging.
  
  
  METHODS
  This retrospective observational case series included 23 eyes of 14 patients with central serous chorioretinopathy treated by a single physician (L.A.Y.) with either spironolactone, eplerenone, or both consecutively over a 12-month period. Choroidal thickness, central macular thickness, and best-corrected visual acuity were measured and compared with baseline values. Twelve eyes of 11 patients demonstrated subretinal fluid before or during the initiated treatment course. Subretinal fluid was measured and compared with baseline values in this subgroup.
  
  
  RESULTS
  In all eyes (n = 23), best-corrected visual acuity improved at 12 months of treatment; however, central macular thickness and choroidal thickness showed no improvement. In the subgroup with subretinal fluid (n = 12), subretinal fluid was significantly decreased at 6 months and 12 months of treatment; however, central macular thickness, choroidal thickness, and best-corrected visual acuity showed no significant change.
  
  
  CONCLUSIONS
  Mineralocorticoid antagonists may improve best-corrected visual acuity and decrease subretinal fluid in patients with central serous chorioretinopathy, but do not affect the choroidal or macular thickness. This pilot study demonstrates that mineralocorticoid receptor antagonists may be effective in treating central serous chorioretinopathy but warrants consideration for future research within a randomized clinical trial.
authors.affiliation: *Department of Ophthalmology, New York University School of Medicine, New York, New York; †Vitreous-Retina-Macula Consultants of New York, New York, New York; ‡LuEsther T. Mertz Retinal Research Center, Manhattan Eye, Ear, and Throat Hospital, New York, New York; §Edward S. Harkness Eye Institute, Columbia University College of Physicians and Surgeons, New York, New York; ¶Department of Ophthalmology, Shanghai First People's Hospital, Shanghai Jiaotong University, Shanghai, China; and **Weill Cornell Medical College, New York, New York.
authors.forename: Quraish
authors.initials: Q
authors.lastname: Ghadiali
authors.forename: Jesse J
authors.initials: JJ
authors.lastname: Jung
authors.forename: Suqin
authors.initials: S
authors.lastname: Yu
authors.forename: Samir N
authors.initials: SN
authors.lastname: Patel
authors.forename: Lawrence A
authors.initials: LA
authors.lastname: Yannuzzi
mesh_terms: D000328:Adult; D000368:Aged; D056833:Central Serous Chorioretinopathy / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D000077545:Eplerenone; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D000451:Mineralocorticoid Receptor Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D064847:Multimodal Imaging; D010865:Pilot Projects; D012189:Retrospective Studies; D013148:Spironolactone / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D058471:Subretinal Fluid; D014792:Visual Acuity / Q000502:physiology
chemical_list: D000451:Mineralocorticoid Receptor Antagonists; D013148:Spironolactone; D000077545:Eplerenone